FDA has indicated Gavreto (pralsetinib) from Blueprint Medicines to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
The drug was formerly known as BLU-667 and won FDA approval in September 2020.
CStone, which is developing the drug in China, received approval from that country’s regulatory authority, making it the first novel therapy for locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy.
Filed Under: Oncology
Tell Us What You Think!
You must be logged in to post a comment.